#Azenta
$AZTA Azenta Beats Q4 Estimates, Stock Now 20% Above New Analyst Target
Azenta Q4 Beat Sends Stock Past Analyst Target
Azenta beat Q4 2026 earnings estimates and closed Wednesday at $48.9, roughly 20% above a freshly raised $40.2 analyst target, as 21.7% short float amplified the move.
www.basisreport.com
November 12, 2026 at 2:20 PM
Azenta Announces Fourth Quarter and Full Year Financial Results for Fiscal Year 2026 Ending September 30, 2026#USA#Burlington#financial_results#Life_Sciences#Azenta_Inc
Azenta Announces Fourth Quarter and Full Year Financial Results for Fiscal Year 2026 Ending September 30, 2026
Azenta Inc. has revealed its fiscal 2026 financial report, showcasing significant revenue growth and strategic acquisitions aimed at enhancing its offerings in the life sciences sector.
third-news.com
November 10, 2026 at 9:58 PM
Azenta $AZTA reported Q4 2026 Adj EPS of $0.28, beating the $0.15 estimate by 86.7%. Revenue of $167.1M beat the $157.4M estimate by 6.2%.

https://fundspec.ai/s/AZTA/earnings
Pick a trader profile and get signals tuned to how you actually trade.
November 10, 2026 at 9:35 PM
🚨 $AZTA
On November 10, 2026, Azenta, Inc. issued a press release announcing financial results for the fiscal quarter and year ended September 30, 2026. A copy of the release is furnished herewith as Exhibit 99.1 and incorporated by reference herein.
SEC Filing: AZTA
Click to view the official SEC document.
www.sec.gov
November 10, 2026 at 9:59 PM
#$AZTA: Off-exchange (dark pool) shares, % of volume: Nov 11 1,208,637 (48.6%).
#$AZTA drew $741K in options premium: calls $720K, puts $21K (97% calls).

Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days.

Full story at the link.
#darkpool #stocks #stockmarket
Azenta (AZTA) Technical Levels: Options Flow, Dark Pools Line Up Above $38.32
AZTA at $48.90: support $38.32, resistance $50.05; the chart, options flow and dark pools line up bullish.
globaltradersacademy.com
November 12, 2026 at 3:07 AM
Sunday Round-Up · 2–7 November 2026

The week's largest buys: Keith Meister $51.7m of MGM Resorts, RA Capital $46.6m of Bambusa Therapeutics, Baker Bros. $35.0m of Madrigal, and Richard Kinder $15.0m of Kinder Morgan.

53 Pings across six days. Free: tetraradar.com
November 8, 2026 at 10:30 AM
🚨 JUST IN: $AZTA
Azenta takes exclusive Elegen gene-synthesis license and buys SynPlexity to expand GENEWIZ

#SEC #stocks #investing #AZTA #Mergers
🔗 secwatch.observer
October 30, 2026 at 2:00 PM
Always nice to see a startup exit. This time, it's Azenta Life Sciences picking up SynPlexity, a University of Oregon spin out and Launch Oregon portfolio company. siliconflorist.com/2026/10/30/a...
Azenta acquires SynPlexity, a University of Oregon spinout – Portland Oregon startups, tech, news, events, jobs, and community
SynPlexity is a Eugene company, based at the University of Oregon’s Knight Campus. It was cofounded by Knight Campus bioengineering professor Calin Plesa. And it was a University of Oregon sp…
siliconflorist.com
October 30, 2026 at 4:30 PM
Azenta is expanding gene synthesis with an exclusive licensing deal with Elegen Corp. and its purchase of synthetic-biology firm SynPlexity. The additions bring new platforms to its GENEWI…
https://aiseek.dev/en/stories/af7583b4-170c-4574-a4cb-6d063ae3dcb2
October 30, 2026 at 2:00 PM
Azenta's Bold Investments Set to Transform GENEWIZ Gene Synthesis Landscape#United_States#Burlington#Azenta#GENEWIZ#SynPlexity
Azenta's Bold Investments Set to Transform GENEWIZ Gene Synthesis Landscape
Azenta, Inc. announces significant investments to boost GENEWIZ's gene synthesis capabilities, enhancing growth potential and innovation in biotechnologies.
third-news.com
October 30, 2026 at 12:17 PM
Azenta Announces Strategic Investments to Advance the Next Generation of GENEWIZ Gene Synthesis Capabilities
Azenta (Nasdaq: AZTA) expanded its GENEWIZ gene synthesis capabilities through an exclusive licensing agreement with Elegen and the acquisition of SynPlexity.The Elegen license adds a cell-free DNA synthesis platform designed to improve DNA quality, delivery speed and manufacturing scalability. It includes sequence-verified DNA constructs and templates for downstream experiments, including antibody discovery. Compact production workflows allow regional capacity to be added near customers as needed.The completed SynPlexity acquisition adds pooled gene assembly technology that provides thousands of full-length gene variants in a single library, supporting the testing of large numbers of candidates, including AI-generated designs. Azenta expects the investments to expand GENEWIZ's customer offerings and accelerate its growth.
www.stocktitan.net
October 30, 2026 at 12:00 PM
Azenta to Host Key Earnings Conference Call for Fiscal 2026 Results#United_States#Burlington#Earnings#Conference_Call#Azenta
Azenta to Host Key Earnings Conference Call for Fiscal 2026 Results
Azenta, Inc. is set to announce its fiscal Q4 and full year 2026 earnings on November 10, with a conference call following the next day.
third-news.com
October 28, 2026 at 8:23 PM
MODERNA, PROGYNY, AZENTA, OSCAR HEALTH AND AGILON HEALTH SHARES RISE ON ELECTION OUTLOOK AND HEALTHCARE SPENDING EXPECTATIONS
October 19, 2026 at 6:47 PM